<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923347</url>
  </required_header>
  <id_info>
    <org_study_id>212655</org_study_id>
    <nct_id>NCT04923347</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety, Efficacy and Tolerability of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in Participants With Chronic Obstructive Pulmonary Disease in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety, efficacy and tolerability of FF/UMEC/VI via ELLIPTAÂ®&#xD;
      inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 25, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive FF/UMEC/VI via ELLIPTA inhaler.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in trough forced expiratory volume in 1 second (FEV1) at Days 28, 84, 85</measure>
    <time_frame>Baseline (Day 1) and at Days 28, 84, 85</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Participants receiving FF/UMEC/VI via ELLIPTA inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/UMEC/VI</intervention_name>
    <description>FF/UMEC/VI will be administered</description>
    <arm_group_label>Participants receiving FF/UMEC/VI via ELLIPTA inhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ELLIPTA</intervention_name>
    <description>Participants will receive FF/UMEC/VI using ELLIPTA inhaler.</description>
    <arm_group_label>Participants receiving FF/UMEC/VI via ELLIPTA inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  A signed and dated written informed consent prior to study participation&#xD;
&#xD;
          -  Participants 40 years of age or older at Screening (Visit 1)&#xD;
&#xD;
          -  Male and female participants will be included in the study. A female participant is&#xD;
             eligible to participate if she is not pregnant, not breastfeeding, and at least one of&#xD;
             the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A&#xD;
             WOCBP who agrees to follow the contraceptive guidance during the treatment period and&#xD;
             until the safety follow-up contact after the last dose of study intervention.&#xD;
&#xD;
          -  An established clinical history of COPD in accordance with the definition by the&#xD;
             American Thoracic Society/European Respiratory Society.&#xD;
&#xD;
          -  Current or former cigarette smokers with a history of cigarette smoking of greater&#xD;
             than equal to (&gt;=)10 pack-years at Screening (Visit 1) (number of pack years = [number&#xD;
             of cigarettes per day divided by 20] times number of years smoked [for example 20&#xD;
             cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]). Previous&#xD;
             smokers are defined as those who have stopped smoking for at least 6 months prior to&#xD;
             Visit 1.&#xD;
&#xD;
          -  A score of &gt;=10 on the COPD Assessment Test (CAT) at Screening (Visit 1).&#xD;
&#xD;
          -  Participants must demonstrate at Screening: A post-bronchodilator FEV1 less than (&lt;)&#xD;
             50 percent (%) predicted normal or a post-bronchodilator FEV1 50-&lt;80% predicted normal&#xD;
             and a documented history of &gt;=2 moderate exacerbations or one severe (hospitalized)&#xD;
             exacerbation in the previous 12 months. Participants must also have a measured post&#xD;
             salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of &lt;0.70 at screening.&#xD;
&#xD;
          -  Participant must be receiving daily long-acting maintenance treatment for their COPD&#xD;
             for at least 3 months prior to Screening. To ensure participants enrolled are&#xD;
             representative of the population that may be eligible for single inhaler triple&#xD;
             therapy in India, prescription data from India will be used to cap the approximate&#xD;
             number of participants enrolled on the most widely prescribed COPD medications.&#xD;
&#xD;
          -  A negative test for active Coronavirus Disease 2019 (COVID-19) at Visit 1. The test&#xD;
             should be done using a molecular (Polymerase chain reaction [PCR] or antigen test)&#xD;
             approved by the country regulatory authorities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating or are planning on becoming pregnant during the&#xD;
             study.&#xD;
&#xD;
          -  Participants with a current diagnosis of asthma. (Participants with a prior history of&#xD;
             asthma are eligible if they have a current diagnosis of COPD).&#xD;
&#xD;
          -  Participants with alpha 1-antitrypsin deficiency as the underlying cause of COPD.&#xD;
&#xD;
          -  Participants with active tuberculosis, lung cancer, and clinically significant (in the&#xD;
             opinion of the investigator): bronchiectasis, sarcoidosis, lung fibrosis, pulmonary&#xD;
             hypertension, interstitial lung diseases or other active pulmonary diseases&#xD;
&#xD;
          -  Participants with lung volume reduction surgery within the 12 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least&#xD;
             14 days prior to Screening and at least 30 days following the last dose of&#xD;
             oral/systemic corticosteroids (if applicable). In addition, any participant that&#xD;
             experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in&#xD;
             period will be excluded.&#xD;
&#xD;
          -  Respiratory tract infection that has not resolved at least 7 days prior to Screening.&#xD;
&#xD;
          -  Participants with known COVID-19 positive contacts within the past 14 days should be&#xD;
             excluded for at least 14 days since the exposure and the participant remains symptom&#xD;
             free. Participants with symptoms suggestive of active COVID-19 infection e.g. fever,&#xD;
             cough (new or worsened), etc. are also excluded.&#xD;
&#xD;
          -  Chest x-ray (poster anterior and lateral) reveals evidence of pneumonia or a&#xD;
             clinically significant abnormality not believed to be due to the presence of COPD, or&#xD;
             another condition that would hinder the ability to detect an infiltrate on chest x-ray&#xD;
             (CXR) (e.g. significant cardiomegaly, pleural effusion or scarring).&#xD;
&#xD;
          -  Participants with historical or current evidence of clinically significant&#xD;
             cardiovascular, neurological, psychiatric, renal, hepatic, immunological,&#xD;
             gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory,&#xD;
             endocrine (including uncontrolled diabetes or thyroid disease) or hematological&#xD;
             abnormalities that are uncontrolled.&#xD;
&#xD;
          -  Abnormal and clinically significant 12-lead electrocardiogram (ECG) finding at Visit&#xD;
             1.&#xD;
&#xD;
          -  Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy &gt;3 Liters&#xD;
             per minute (L/min) at screening (Oxygen use &lt;=3L/min flow at rest is not&#xD;
             exclusionary.)&#xD;
&#xD;
          -  Participants must not start the acute phase of a pulmonary rehabilitation program&#xD;
             within the 4 weeks prior to Visit 1.&#xD;
&#xD;
          -  Participants who are medically unable to withhold their salbutamol for the 4-hour&#xD;
             period required prior to spirometry testing at each study visit.&#xD;
&#xD;
          -  In the opinion of the investigator, any participant who is unable to read and/or would&#xD;
             not be able to complete study related materials.&#xD;
&#xD;
          -  Use of the following medications within the following time intervals prior to Visit 1&#xD;
             or during the study:&#xD;
&#xD;
          -  Participants receiving antibiotics for long term therapy are not eligible for the&#xD;
             study.&#xD;
&#xD;
          -  No use of systemic, Oral, parenteral corticosteroids within 30 days prior to screening&#xD;
             (Intra-articular injections are allowed).&#xD;
&#xD;
          -  No use of any other investigational drug within 30 days or 5 half-lives whichever is&#xD;
             longer prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>ELLIPTA</keyword>
  <keyword>Fluticasone Furoate</keyword>
  <keyword>Umeclidinium</keyword>
  <keyword>Vilanterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

